Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301

Read the full 147 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE